Celltrion Files Phase 4 IND with FDA to Support 240 mg High-Dose Zymfentra Regimen in US
Celltrion has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for a Phase 4 clinical trial of Zymfentra...
Search results for "United States"
The "Complete Protein" Myth: How Animal Meat Triggers Cancer, Hypertension, and Diabetes
Animal protein is widely celebrated as a "complete protein" because it contains all essential amino acids.
Hanmi Completes Key Phase 2 Dosing for Once-Weekly Rare Disease Drug Efpeglucagon
During normal digestion, dietary carbohydrates convert into glucose that circulates in the blood.
SK Plasma Launches High-Dose Revolpag 75 mg to Simplify Thrombocytopenia Regimens and Cut Costs
SK Plasma announced on Sept. 1 that it has begun distributing Revolpag Tablets 75 mg in South Korea, expanding its...
Zymfentra U.S. Sales Surge 176% as Celltrion’s Remsima Franchise Eyes 1 Trillion Won Annual Revenue
Biopharmaceutical company Celltrion announced on Aug. 27 that combined first-half sales of its subcutaneous infliximab...
Celltrion Files for South Korean Approval of Keytruda Biosimilar CT-P51
Celltrion announced on August 24 that it has submitted a marketing authorization application to South Korea’s Ministry...
Korea University Anam Hospital hosts ‘2026 Mongolia Patients’ Night’ in Ulaanbaatar
Korea University Anam Hospital’s International Healthcare Center hosted the "2026 Mongolia Patients’ Night" on August...
Hanmi Licenses Muscle-Preserving Obesity Drug Candidate to Genentech in $2.3 Billion Deal
Hanmi Pharmaceutical has entered into an exclusive global licensing agreement with Genentech, a member of the Roche...
Taking Leqembi Isn’t Enough: Only 3% of Early Alzheimer’s Patients Follow Recommended Lifestyle Habits
The arrival of disease-modifying treatments capable of slowing Alzheimer’s progression has offered patients newfound...
AbTis Wins U.S. Patent Ruling, Safeguarding Core Rights to AbClick Platform
Antibody-drug conjugate developer AbTis announced on August 14 that it has prevailed in an inter partes review before...